Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...

Guselkumab is the first IL-23 inhibitor approved for Crohn's disease with subcutaneous and intravenous options, targeting inflammation by blocking IL-23 and binding to CD64. The GRAVITI study ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48.

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study ...

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...